These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 12661270)

  • 21. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.
    Rocca A; Peruzzotti G; Ghisini R; Viale G; Veronesi P; Luini A; Intra M; Pietri E; Curigliano G; Giovanardi F; Maisonneuve P; Goldhirsch A; Colleoni M
    Anticancer Drugs; 2006 Nov; 17(10):1201-9. PubMed ID: 17075320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can the addition of prophylactic filgrastim be considered cost effective in early breast cancer patients treated with epirubicin and cyclophosphamide?
    Ferretti G; Papaldo P
    J Clin Oncol; 2006 Dec; 24(35):5615-6; author reply 5616. PubMed ID: 17158552
    [No Abstract]   [Full Text] [Related]  

  • 25. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anthracyclines in the adjuvant treatment of breast carcinoma: thirty years later].
    Lopez M
    Clin Ter; 2006; 157(2):165-77. PubMed ID: 16817507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
    Gennari A; Amadori D; De Lena M; Nanni O; Bruzzi P; Lorusso V; Manzione L; Conte PF
    J Clin Oncol; 2006 Aug; 24(24):3912-8. PubMed ID: 16921042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study.
    Barni S; Visini M; Piazza E; Ionta MT; Ardizzoia A; Arnoldi E; Fava S; Pinotti G; Torretta F; Corradini G; Villa S; Nosenzo AM; Massidda B; Cazzaniga ME
    Anticancer Res; 2007; 27(4C):3019-24. PubMed ID: 17695490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
    Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
    PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer.
    Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Cold S; Edlund P; Ewertz M; Jensen BB; Kamby C; Nordenskjold B; Bergh J
    Eur J Cancer; 2007 Mar; 43(5):877-84. PubMed ID: 17306974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
    J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line chemotherapy with fluorouracil-epirubicin-navelbine (FEN) combination in advanced breast cancer.
    Ardavanis A; Tryfonopoulos D; Orphanos G; Ioannidis G; Karamouzis M; Rigatos G
    Anticancer Res; 2005; 25(6C):4493-8. PubMed ID: 16334132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aggressive chemotherapy for the treatment of breast cancer.
    Greenspan EM
    J Clin Oncol; 1985 Jul; 3(7):1043. PubMed ID: 4020402
    [No Abstract]   [Full Text] [Related]  

  • 37. Chemotherapy of advanced breast cancer.
    Herrmann R
    J Clin Oncol; 1988 Oct; 6(10):1665-6. PubMed ID: 3171632
    [No Abstract]   [Full Text] [Related]  

  • 38. [Advances in intercalating drugs].
    Pouillart P; Beuzeboc P; Dorval T; Garcia-Giralt E; Jouve M; Palangie T; School S
    Pathol Biol (Paris); 1989 Feb; 37(2):159-60. PubMed ID: 2652071
    [No Abstract]   [Full Text] [Related]  

  • 39. Survival in advanced breast cancer. Combination chemotherapy improves outlook.
    Price LA
    BMJ; 1994 Apr; 308(6936):1103. PubMed ID: 8173443
    [No Abstract]   [Full Text] [Related]  

  • 40. Landmark study demonstrates survival benefit at 10 years for breast cancer patients.
    Oncology (Williston Park); 2003 Mar; 17(3):387. PubMed ID: 12661270
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.